ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (FRA:R9Z)

Market Cap	142.34M -67.1%
Revenue (ttm)	19.01M +25.6%
Net Income	-29.66M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	0.3100
Previous Close	0.3100
Day's Range	0.3100 - 0.3100
52-Week Range	0.2940 - 0.9750
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About FRA:R9Z

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 197
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R9Z

Financial Performance

In 2025, FRA:R9Z's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error